ES2145072T3 - Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos. - Google Patents

Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.

Info

Publication number
ES2145072T3
ES2145072T3 ES94106827T ES94106827T ES2145072T3 ES 2145072 T3 ES2145072 T3 ES 2145072T3 ES 94106827 T ES94106827 T ES 94106827T ES 94106827 T ES94106827 T ES 94106827T ES 2145072 T3 ES2145072 T3 ES 2145072T3
Authority
ES
Spain
Prior art keywords
membrane proteins
gramnegative
coconuts
preparation
external membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106827T
Other languages
English (en)
Inventor
Gary W Zlotnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2145072T3 publication Critical patent/ES2145072T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

AQUI SE DESCRIBE UN METODO PARA ELIMINAR LIPOOLIGOSACARIDOS (LOS) TOXICOS DE LAS MEMBRANAS EXTERIORES DE COCOS GRAM EGATIVOS, TALES COMO NEISSERIA MENINGITIDIS. PROTEINAS DE MEMBRANAS EXTERIORES VACIADAS DE LOS Y DE MEMBRANAS SOLUBLES EXTERIORES VACIADAS DE LOS PUEDEN SER PREPARADAS, LAS CUALES SON VALIDAS PARA EXTRAER ANTICUERPOS BACTERICIDAS CONTRA CEPAS HOMOLOGAS DE BACTERIA. VACUNAS Y OTROS USOS DE LAS PREPARACIONES SON DESCRITAS ADICIONALMENTE.
ES94106827T 1993-05-13 1994-05-02 Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos. Expired - Lifetime ES2145072T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6158193A 1993-05-13 1993-05-13

Publications (1)

Publication Number Publication Date
ES2145072T3 true ES2145072T3 (es) 2000-07-01

Family

ID=22036711

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106827T Expired - Lifetime ES2145072T3 (es) 1993-05-13 1994-05-02 Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.

Country Status (11)

Country Link
US (2) US6355253B1 (es)
EP (1) EP0624376B1 (es)
JP (1) JP3711289B2 (es)
KR (1) KR100355961B1 (es)
AT (1) ATE190502T1 (es)
CA (1) CA2123355C (es)
DE (1) DE69423383T2 (es)
DK (1) DK0624376T3 (es)
ES (1) ES2145072T3 (es)
GR (1) GR3033469T3 (es)
PT (1) PT624376E (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
ATE372376T1 (de) * 1997-05-28 2007-09-15 Novartis Vaccines & Diagnostic Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
US20040087020A1 (en) 1997-05-28 2004-05-06 Chiron S.P.A. Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
EP0991761B1 (en) * 1997-08-21 2008-01-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
BR9910749A (pt) 1998-05-29 2001-02-13 Chiron Corp Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
EP2270173B1 (en) 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
MXPA06007635A (es) 2003-12-30 2007-01-30 Wyeth Corp Formulaciones de proteinas hidrofobas en una composicion inmunogenica que tiene tolerabilidad mejorada.
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
KR100612895B1 (ko) * 2005-05-04 2006-08-14 삼성전자주식회사 화학 물질을 이용한 생물학적 시료로부터 단백질의선택적인 제거 방법
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5723768B2 (ja) * 2008-05-30 2015-05-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
JP6546654B2 (ja) 2014-08-22 2019-07-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 淋菌感染を治療するための三環式含窒素化合物
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110568116A (zh) * 2019-09-17 2019-12-13 广东医科大学附属医院 一种筛选用于诊断阿尔茨海默病的生物标志物的方法
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4386066A (en) * 1981-08-20 1983-05-31 Merck & Co., Inc. Immunogenic complex from N. gonorrhoeae
WO1983003354A1 (en) 1982-03-30 1983-10-13 Us Army Neisseria gonorrhoeae vaccine
NL8403195A (nl) 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
DE3516017A1 (de) 1985-05-02 1986-11-27 Jochen 1000 Berlin Kittel Verfahren zur herstellung membranstaendiger proteine aus biologischem material zur anwendung im biologischen systemen
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
CA1338708C (en) * 1988-06-29 1996-11-12 Lee Mark Wetzler Neisserial vaccines
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
DE69033600T2 (de) 1989-03-09 2001-04-05 American Cyanamid Co., Madison Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
AU638453B2 (en) 1989-04-14 1993-07-01 Inverness Medical Switzerland Gmbh Extraction of solubilized antigens
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis

Also Published As

Publication number Publication date
PT624376E (pt) 2000-07-31
US6355253B1 (en) 2002-03-12
GR3033469T3 (en) 2000-09-29
ATE190502T1 (de) 2000-04-15
JPH0819396A (ja) 1996-01-23
JP3711289B2 (ja) 2005-11-02
DE69423383T2 (de) 2000-08-24
CA2123355C (en) 2007-08-28
CA2123355A1 (en) 1994-11-14
EP0624376A1 (en) 1994-11-17
US20020136741A1 (en) 2002-09-26
EP0624376B1 (en) 2000-03-15
KR100355961B1 (ko) 2002-12-26
DK0624376T3 (da) 2000-07-24
DE69423383D1 (de) 2000-04-20
US6921537B2 (en) 2005-07-26

Similar Documents

Publication Publication Date Title
ES2145072T3 (es) Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
AU4841693A (en) Vaccines against group c neisseria meningitidis
Kim et al. Characterization of Antigens from Aspergillus Fumigatus: I. Preparation of Antigens from Organisms Grown in Completely Synthetic Medium
IE853227L (en) Modified polysaccharides and their conjugates with¹immunogenic proteins
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
NO319013B1 (no) Vaksine omfattende type I overflateantigener fra Staphylococcus epidermidis, samt hyperimmune globuliner og antistoff rettet mot type I-overflateantigenet.
WO1990006696A3 (en) Meningococcal class 1 outer-membrane protein vaccine
DK1051506T3 (da) Fremgangsmåde til ekstraktion og isolation af bakterielle kapsel-polysaccharider til anvendelse som vaccine eller sammenkoblet med proteiner som konjugerede vacciner
IE840197L (en) Polysaccharide protein conjugate vaccine
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
Kamstrup et al. Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A
DK0754055T3 (da) Gruppe A-streptokok-polysaccharid-immunogen-præparater og metoder
HUT35521A (en) Process for preparing a pharmaceutical composition containing a purified, detixicated endotoxine and a pyridine soluble extract of a microorganism
DK0480949T4 (da) Fremstilling af virusvaccine
Bromuro et al. Differential release of an immunodominant 65 kDa mannoprotein antigen from yeast and mycelial forms of Candida albicans
IT1254360B (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
ES466359A1 (es) Procedimiento para preparar vacunas vivas e inactivas del virus de la rabia.
Vijay et al. Studies on Alternaria Allergens: V. Comparative Biochemical and Immunological Studies of Three Isolates of Alternaria tenuis Cultured on Synthetic Media
RU2185191C1 (ru) Способ получения антигенного препарата haemophilus influenzae типа b (hib)
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
RU2542393C2 (ru) СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТА КАПСУЛЬНОГО ПОЛИСАХАРИДА Haemophilus influenzae ТИП b (Hib) C АНТИГЕНАМИ ДЛЯ СОЗДАНИЯ ИММУНОБИОЛОГИЧЕСКИХ ПРЕПАРАТОВ
SU1527256A1 (ru) Питательна среда дл культивировани микоплазм
NO874391L (no) Nye gjaerekspresjonsvektorer for ifn-omega samt fremgangsmaate for fremstilling og anvendelse derav.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624376

Country of ref document: ES